Latest cell therapy Stories
WASHINGTON, April 22, 2013 /PRNewswire-USNewswire/ -- Family Research Council (FRC) congratulated Kansas Governor Sam Brownback and the state of Kansas for the passage and signing of Kansas SB 199. The law establishes a new adult stem cell research and treatment center at the University of Kansas Medical Center in Kansas City's medical school. (Logo: http://photos.prnewswire.com/prnh/20080930/FRCLOGO) FRC's Senior Fellow Dr. David Prentice has testified in Kansas for years about...
Treatment that consisted of shock wave (procedure using high-dose ultrasound)-mediated preconditioning of the target heart tissue prior to administration of bone marrow-derived mononuclear cells was associated with significant, albeit modest improvement in left ventricular ejection fraction (a measure of how well the left ventricle of the heart pumps with each contraction) after 4 months in patients with chronic postinfarction heart failure, according to a study in the April 17 issue of JAMA....
Trial Expands to Two Centers; Approval Includes Significant Increase in Dosing ROCKVILLE, Md., April 17, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has received approval from the Food and Drug Administration (FDA) to commence a Phase II trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This Phase II dose escalation and safety trial will expand to two centers,...
Patent-pending PRCN-829 delivers multiple genes, including Factor H, neural growth factors and regulators of TDP-43 to treat neurodegenerative disease ALS BOGOTA, Colombia, April 12, 2013 /PRNewswire/ -- Startup biotechnology company Neuralgene (http://neuralgene.com) has announced that it will begin animal studies in May to evaluate the efficacy of PRCN-829, its new gene therapy agent for the treatment of amyotrophic lateral sclerosis (ALS). PRCN-829 is the first gene therapy...
Heidi M. Hagen, a noted authority on Biotech Cell Manufacturing, Joins as Head of Global Operations Strategy NEW YORK, April 11, 2013 /PRNewswire-iReach/ -- SOTIO a.s, a leader in cell therapy treatments for cancer and autoimmune diseases, has added to their senior leadership team with the addition of Heidi M. Hagen as Chief Operating Officer-US and Head of Global Operations Strategy. As the strategic advisor to SOTIO, Epsen Fuller Group completed the successful placement, which...
MONT-SAINT-GUIBERT, Belgium, April 11, 2013 /PRNewswire/ -- Trial Demonstrates Statistically Significant Improvements in Heart Function and Exercise Tolerance with Cardiopoietic Stem Cell Therapy Cardio3 BioSciences (C3BS) announces today the advanced publication of C-CURE (Phase II) trial results in the on-line edition of the Journal of the American College of Cardiology (JACC).1 The publication reported: - Statistically...
Two Steps Closer to a Viable Treatment for Spinal Cord Injuries GREENWICH, Conn., April 5, 2013 /PRNewswire/ -- Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics (NVIV), for its recent approvals from the U.S. Food and Drug Administration (FDA). On the heels of FDA approval for Humanitarian Use Device (HUD) designation (an important benchmark and speed-to-market catalyst), InVivo has received yet...
ROCKVILLE, Md., April 5, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that it received a notice of allowance for patent application 12/404,841. This patent covers methods for treating amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) with expanded spinal cord stem cells, including NSI-566. Neuralstem completed a Phase I safety trial of its NSI-566 stem cells in ALS earlier this year, for which it has also been granted an Orphan Drug Designation. The...
April Flowers for redOrbit.com - Your Universe Online A new study from the University of California, San Francisco (UCSF) reveals that treating patients with cells may one day become as common as it is now to treat the sick with drugs from engineered proteins, antibodies, or smaller chemicals. The team outlines their vision of cell-based therapy as a "third pillar of medicine" in an online edition of Science Translational Medicine. "Today, biomedical science sits on the cusp of a...
Dr. Saud A. Sadiq to Discuss Cellular Therapy for MS at the Second International Adult Stem Cell Conference: Regenerative Medicine – A Fundamental Shift in Science and Culture. New York, NY (PRWEB) April 03, 2013 The Tisch MS Research Center of New York announced today that Dr. Saud A. Sadiq has accepted an invitation to participate in the Second International Adult Stem Cell Conference: Regenerative Medicine - A Fundamental Shift in Science and Culture to be held within the Vatican,...
